RenovoRx
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 8
- Market Cap
- -
- Website
- http://www.renovorx.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
PanTheR Registry Trial
- Conditions
- Solid Tumors
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- RenovoRx
- Target Recruit Count
- 1000
- Registration Number
- NCT06805461
- Locations
- 🇺🇸
Baptist Health South Florida, Coral Gables, Florida, United States
🇺🇸The University of Vermont Medical Center, Burlington, Vermont, United States
🇺🇸University of Pennsylvania Medical Center, Pittsburgh, Pennsylvania, United States
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- Conditions
- Locally Advanced Pancreatic Cancer
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- RenovoRx
- Target Recruit Count
- 190
- Registration Number
- NCT03257033
- Locations
- 🇺🇸
VA Loma Linda Healthcare System, Loma Linda, California, United States
🇺🇸Sutter Cancer Center Sacramento, Sacramento, California, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter
- Conditions
- Pancreatic Neoplasms
- First Posted Date
- 2015-10-29
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- RenovoRx
- Target Recruit Count
- 25
- Registration Number
- NCT02591082
- Locations
- 🇺🇸
Good Samaritan Hospital, San Jose, California, United States
🇺🇸Fawcett Memorial Hospital, Port Charlotte, Florida, United States
🇺🇸Florida Hospital, Tampa, Florida, United States
A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Gemcitabine, local delivery
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- RenovoRx
- Target Recruit Count
- 20
- Registration Number
- NCT02237157
- Locations
- 🇺🇸
El Camino Hospital, Oncology, Mountain View, California, United States
🇺🇸Florida Hospital, Tampa, Florida, United States
News
RenovoRx Reports Strong Q2 2025 Commercial Growth and Positive Phase III Trial Continuation
RenovoRx achieved over $400,000 in second quarter 2025 revenue from commercial sales of its FDA-cleared RenovoCath drug-delivery device, marking strong growth in its first two full quarters of commercialization.
RenovoRx Launches Multi-Center PanTheR Registry Study to Evaluate Real-World Safety of RenovoCath Device
RenovoRx has launched the PanTheR Post-Marketing Registry Study, a multi-center observational study designed to evaluate the long-term safety and real-world effectiveness of the FDA-cleared RenovoCath drug-delivery device in patients with solid tumors.
Pancreatic Cancer Pipeline Expands with 80+ Companies Advancing Novel Therapies
DelveInsight's 2025 report reveals over 80 companies are actively developing more than 80 pipeline therapies for pancreatic ductal adenocarcinoma treatment.
RenovoRx Secures New U.S. Patent for TAMP Therapy Platform, Strengthening IP Portfolio for Targeted Cancer Treatment
RenovoRx received U.S. patent NO. 12,290,564 for "Methods for Treating Tumors," expanding protection of its Trans-Arterial Micro-Perfusion (TAMP) therapy platform through November 2037.
Johns Hopkins Medicine Joins RenovoRx's Phase III Pancreatic Cancer Trial as New Enrollment Site
Johns Hopkins Medicine has initiated patient enrollment for RenovoRx's Phase III TIGeR-PaC clinical trial, evaluating a novel targeted therapy approach for locally advanced pancreatic cancer.
Clinical Trial Success: Industry Expert Outlines Key Strategies for Better Site Engagement
RenovoRx's Chief Clinical Officer emphasizes the importance of realistic expectations, responsiveness, and transparency in managing clinical trial site relationships and performance.
RenovoRx Secures $12.1M Through Public Offering to Advance Pancreatic Cancer Trial
RenovoRx has announced a public offering of 11.52 million shares at $1.05 per share, aiming to raise $12.1 million in gross proceeds for its clinical research initiatives.
OCT West Coast 2025 Conference to Focus on Trial Efficiency, AI Integration, and Patient-Centricity
Arena International's OCT West Coast 2025 conference will convene in San Francisco on February 11-12, featuring four specialized streams addressing clinical operations, innovation, patient engagement, and medical devices.
RenovoRx's TAMP Platform Shows Promise in Targeted Cancer Therapy
RenovoRx's TAMP platform delivers targeted therapy directly to tumors, potentially minimizing systemic toxicities compared to IV treatments.
RenovoRx Announces Investor Fireside Chat and Provides Update on TIGeR-PaC Trial
RenovoRx will host an investor fireside chat on December 17, 2024, to discuss 2024 achievements and the 2025 outlook, focusing on RenovoCath commercialization.